The Role of Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) in Tumors and Other Diseases

Abstract

Glycoprotein non-metastatic melanoma protein B (GPNMB) is a highly conserved transmembrane glycoprotein, which is widely involved in biological processes of tissues, cells, metabolism and immunity, regulates various signaling pathways, and plays an important role in the occurrence and development of diseases. However, the effect of GPNMB on the same biological process varies greatly in different tissues, and its application as a tumor therapeutic target is also a challenge. At the same time, how to balance the multiple effects of GPNMB is also a key issue facing future clinical applications. This paper reviews the role of GPNMB in tissue repair, metabolic regulation, cell aging, immune response, and the mechanism of GPNMB's involvement in the occurrence and development of various diseases, including tumor. In this paper, we summarize the GPNMB signaling pathway, analyze its potential value as diagnostic markers and therapeutic targets, and discuss the future research direction. Through systematic summary, this review provides a theoretical basis for further understanding of the biological function of GPNMB and its role in diseases, and also provides a new idea for the formulation of GPNMB based precision treatment strategy.

Keywords

biomarker / disease / glycoprotein non-metastatic melanoma protein B / therapeutic

References

[1] M. Kobayashi, J. S. Chung, M. Beg, et al., “Blocking Monocytic Myeloidderived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells From Cancer Patients,” Clinical Cancer Research 25, no. 2 (2019): 828-838.

[2] D. A. Gillett, R. L. Wallings, O. Uriarte Huarte, and M. G. Tansey, “Progranulin and GPNMB: Interactions in Endo-Lysosome Function and Inflammation in Neurodegenerative Disease,” Journal of Neuroinflammation 20, no. 1 (2023): 286.

[3] A. M. Lazaratos, M. G. Annis, and P. M. Siegel, “GPNMB: A Potent Inducer of Immunosuppression in Cancer,” Oncogene 41, no. 41 (2022): 4573-4590.

[4] S. K. Loftus, A. Antonellis, I. Matera, et al., “GPNMB Is a Melanoblast-Expressed, MITF-Dependent Gene,” Pigment Cell & Melanoma Research 22, no. 1 (2009): 99-110.

[5] M. Saade, G. Araujo de Souza, C. Scavone, and P. F. Kinoshita, “The Role of GPNMB in Inflammation,” Frontiers in Immunology 12 (2021): 674739.

[6] V. Bianco and D. Kratky, “Glycoprotein Non-Metastatic Protein B (GPNMB): The Missing Link Between Lysosomes and Obesity,” Experimental and Clinical Endocrinology & Diabetes 131, no. 12 (2023): 639-645.

[7] K. F. Tse, M. Jeffers, V. A. Pollack, et al., “CR011, a Fully Human Monoclonal Antibody-Auristatin E Conjugate, for the Treatment of Melanoma,” Clinical Cancer Research 12, no. 4 (2006): 1373-1382.

[8] C. T. Kuan, K. Wakiya, J. M. Dowell, et al., “Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients With Glioblastoma Multiforme,” Clinical Cancer Research 12, no. 7 Pt 1 (2006): 1970-1982.

[9] F. Tian, C. Liu, Q. Wu, et al., “Upregulation of Glycoprotein Nonmetastatic B by Colony-Stimulating Factor-1 and Epithelial Cell Adhesion Molecule in Hepatocellular Carcinoma Cells,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 20, no. 8 (2013): 341-350.

[10] N. Turque, F. Denhez, P. Martin, et al., “Characterization of a New Melanocyte-Specific Gene (QNR-71) Expressed in V-Myc-Transformed Quail Neuroretina,” EMBO Journal 15, no. 13 (1996): 3338-3350.

[11] F. F. Safadi, J. Xu, S. L. Smock, M. C. Rico, T. A. Owen, and S. N. Popoff, “Cloning and Characterization of Osteoactivin, a Novel CDNA Expressed in Osteoblasts,” Journal of Cellular Biochemistry 84, no. 1 (2001): 12-26.

[12] S. Shikano, M. Bonkobara, P. K. Zukas, and K. Ariizumi, “Molecular Cloning of a Dendritic Cell-Associated Transmembrane Protein, DC-HIL, That Promotes RGD-Dependent Adhesion of Endothelial Cells Through Recognition of Heparan Sulfate Proteoglycans,” Journal of Biological Chemistry 276, no. 11 (2001): 8125-8134.

[13] P. W. Chrystal, T. Footz, E. D. Hodges, J. A. Jensen, M. A. Walter, and W. T. Allison, “Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins,” Molecules 26, no. 12 (2021): 3529.

[14] A. C. Theos, B. Watt, D. C. Harper, et al., “The PKD Domain Distinguishes the Trafficking and Amyloidogenic Properties of the Pigment Cell Protein PMEL and Its Homologue GPNMB,” Pigment Cell & Melanoma Research 26, no. 4 (2013): 470-486.

[15] G. Maric, A. A. Rose, M. G. Annis, and P. M. Siegel, “Glycoprotein Non-Metastatic B (GPNMB): A Metastatic Mediator and Emerging Therapeutic Target in Cancer,” OncoTargets and Therapy 6 (2013): 839-852.

[16] A. A. N. Rose, M. Biondini, R. Curiel, and P. M. Siegel, “Targeting GPNMB With Glembatumumab Vedotin: Current Developments and Future Opportunities for the Treatment of Cancer,” Pharmacology & Therapeutics 179 (2017): 127-141.

[17] Y. Ping, J. Li, L. Xie, et al., “GPNMB Attenuates Neuroinflammation and Improves Ischemic Stroke via Modulation of PI3K/Akt and p38 MAPK Signaling Pathways,” Brain Research 1849 (2025): 149381.

[18] J. S. Chung, K. Sato, I. I. Dougherty, P. D. Cruz , and K. Ariizumi, “DC-HIL Is a Negative Regulator of T Lymphocyte Activation,” Blood 109 (2007): 4320-4327.

[19] R. Xie, Y. Okita, Y. Ichikawa, et al., “Role of the Kringle-Like Domain in Glycoprotein NMB for Its Tumorigenic Potential,” Cancer Science 110, no. 7 (2019): 2237-2246.

[20] C. Chen, Y. Okita, Y. Watanabe, et al., “Glycoprotein NMB Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-Like Properties,” Cancer Research 78, no. 22 (2018): 6424-6435.

[21] G. Maric, M. G. Annis, P. A. MacDonald, et al., “GPNMB Augments Wnt-1 Mediated Breast Tumor Initiation and Growth by Enhancing PI3K/AKT/mTOR Pathway Signaling and β-Catenin Activity,” Oncogene 38, no. 26 (2019): 5294-5307.

[22] A. Prabata, K. Ikeda, E. P. Rahardini, K. I. Hirata, and N. Emoto, “GPNMB Plays a Protective Role Against Obesity-Related Metabolic Disorders by Reducing Macrophage Inflammatory Capacity,” Journal of Biological Chemistry 297, no. 5 (2021): 101232.

[23] G. Bao, N. Wang, R. Li, G. Xu, P. Liu, and B. He, “Glycoprotein Non-Metastaticmelanoma Protein B Promotes Glioma Motility and Angiogenesis Through the Wnt/β-Catenin Signaling Pathway,” Experimental Biology and Medicine 241, no. 17 (2016): 1968-1976.

[24] Misra D. P., Singh K., Sharma A., and Agarwal , “Arterial Wall Fibrosis in Takayasu Arteritis and Its Potential for Therapeutic Modulation,” Frontiers in Immunology 14 (2023): 1174249.

[25] L. Zhou, H. Zhuo, H. Ouyang, et al., “Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) Is Highly Expressed in Macrophages of Acute Injured Kidney and Promotes M2 Macrophages Polarization,” Cellular Immunology 316 (2017): 53-60.

[26] S. Son, H. Kim, H. Lim, J. Lee, K. Lee, and I. Shin, “CCN3/NOV Promotes Metastasis and Tumor Progression via GPNMB-Induced EGFR Activation in Triple-Negative Breast Cancer,” Cell Death & Disease 14, no. 2 (2023): 81.

[27] A. A. N. Rose, M. G. Annis, D. T. Frederick, et al., “MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB,” Clinical Cancer Research 22, no. 24 (2016): 6088-6098.

[28] C. L. Han, X. R. Chen, A. Lan, et al., “N-Glycosylated GPNMB Ligand Independently Activates Mutated EGFR Signaling and Promotes Metastasis in NSCLC,” Cancer Science 112, no. 5 (2021): 1911-1923.

[29] A. A. N. Rose, F. Pepin, C. Russo, J. E. Abou Khalil, M. Hallett, and P. M. Siegel, “Osteoactivin Promotes Breast Cancer Metastasis to Bone,” Molecular Cancer Research 5, no. 10 (2007): 1001-1014.

[30] C. Wang, Y. Okita, L. Zheng, et al., “Glycoprotein Non-Metastatic Melanoma Protein B Functions With Growth Factor Signaling to Induce Tumorigenesis Through Its Serine Phosphorylation,” Cancer Science 112, no. 10 (2021): 4187-4197.

[31] C. Huang, Y. Zheng, R. Ji, et al., “GPNMB Promotes Peripheral Nerve Regeneration by Activating the Erk1/2 and Akt Pathways via Binding Na+/K+-ATpase α1 in Schwann Cells,” Experimental Neurology 373 (2024): 114687.

[32] Y. Lin, Y. Qi, M. Jiang, W. Huang, and B. Li, “Lactic Acid-Induced M2-Like Macrophages Facilitate Tumor Cell Migration and Invasion via the GPNMB/CD44 Axis in Oral Squamous Cell Carcinoma,” International Immunopharmacology 124, no. Pt B (2023): 110972.

[33] X. Zhou, N. Chen, H. Xu, et al., “Regulation of Hippo-Yap Signaling by Insulin-Like Growth Factor-1 Receptor in the Tumorigenesis of Diffuse Large B-Cell Lymphoma,” Journal of Hematology & Oncology 13, no. 1 (2020): 77.

[34] C. Fiorentini, S. Bodei, F. Bedussi, et al., “GPNMB/OA Protein Increases the Invasiveness of Human Metastatic Prostate Cancer Cell Lines DU145 and PC3 Through MMP-2 and MMP-9 Activity,” Experimental Cell Research 323, no. 1 (2014): 100-111.

[35] T. Li, Y. Zhang, Q. Lu, L. Lei, J. Du, and X. Lu, “GPNMB Ameliorates Neuroinflammation via the Modulation of AMPK/NFκB Signaling Pathway After SAH in Mice,” Journal of Neuroimmune Pharmacology 18, no. 4 (2023): 628-639.

[36] T. A. Owen, S. L. Smock, S. Prakash, et al., “Identification and Characterization of the Genes Encoding Human and Mouse Osteoactivin,” Critical Reviews in Eukaryotic Gene Expression 13 (2003): 16.

[37] Y. Xu, M. Wang, L. Zhang, et al., “Glycoprotein Non-Metastatic Melanoma Protein B Restricts PRRSV Replication by Inhibiting Autophagosome-Lysosome Fusion,” Viruses 15, no. 4 (2023): 920.

[38] J. J. Huang, W. J. Ma, and S. Yokoyama, “Expression and Immunolocalization of GPNMB, a Glioma-Associated Glycoprotein, in Normal and Inflamed Central Nervous Systems of Adult Rats,” Brain and Behavior 2 (2012): 85-96.

[39] B. K. Shrestha, B. M. Ward, T. W. Allen, et al., “Characterization of QoI-Fungicide Resistance in Cercospora Isolates Associated With Cercospora Leaf Blight of Soybean From the Southern United States,” Plant Disease 108, no. 1 (2024): 149-161.

[40] B. Yu, G. R. Sondag, C. Malcuit, M. H. Kim, and F. F. Safadi, “Macrophage-Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration via a CD44-Dependent Mechanism,” Journal of Cellular Biochemistry 117, no. 7 (2016): 1511-1521.

[41] B. Yu, T. Alboslemy, F. Safadi, and M. H. Kim, “Glycoprotein Nonmelanoma Clone B Regulates the Crosstalk Between Macrophages and Mesenchymal Stem Cells Toward Wound Repair,” Journal of Investigative Dermatology 138, no. 1 (2018): 219-227.

[42] V. Ramani, J. S. Chung, K. Ariizumi, and P. D. Cruz , “Soluble DC-HIL/GPNMB Modulates T-Lymphocyte Extravasation to Inflamed Skin,” Journal of Investigative Dermatology 142, no. 5 (2022): 1372-1380.e5.

[43] N. Frara, S. M. Abdelmagid, M. Tytell, et al., “Growth and Repair Factors, Osteoactivin, Matrix Metalloproteinase and Heat Shock Protein 72, Increase With Resolution of Inflammation in Musculotendinous Tissues in a Rat Model of Repetitive Grasping,” BMC Musculoskeletal Disorders 17 (2016): 34.

[44] G. R. Sondag, T. S. Mbimba, F. M. Moussa, et al., “Osteoactivin Inhibition of Osteoclastogenesis Is Mediated Through CD44-ERK Signaling,” Experimental & Molecular Medicine 48, no. 9 (2016): e257.

[45] M. H. C. Sheng, J. E. Wergedal, S. Mohan, and K. H. W. Lau, “Osteoactivin Is a Novel Osteoclastic Protein and Plays a Key Role in Osteoclast Differentiation and Activity,” FEBS Letters 582, no. 10 (2008): 1451-1458.

[46] S. M. Abdelmagid, G. R. Sondag, F. M. Moussa, et al., “Mutation In Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-Mediated Osteoclast Differentiation and Survival But Inhibits Osteoclast Function,” Journal of Biological Chemistry 290, no. 33 (2015): 20128-20146.

[47] M. Suda, I. Shimizu, G. Katsuumi, et al., “Senolytic Vaccination Improves Normal and Pathological Age-Related Phenotypes and Increases Lifespan in Progeroid Mice,” Nature Aging 1, no. 12 (2021): 1117-1126.

[48] M. Baba, M. Furuya, T. Motoshima, et al., “TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease,” Molecular Cancer Research 17, no. 8 (2019): 1613-1626.

[49] O. R. Brekk, J. R. Honey, S. Lee, P. J. Hallett, and O. Isacson, “Cell Type-Specific Lipid Storage Changes in Parkinson's Disease Patient Brains Are Recapitulated by Experimental Glycolipid Disturbance,” Proceedings of the National Academy of Sciences 117, no. 44 (2020): 27646-27654.

[50] T. L. Gabriel, M. J. Tol, R. Ottenhof, et al., “Lysosomal Stress in Obese Adipose Tissue Macrophages Contributes to MITF-Dependent GPNMB Induction,” Diabetes 63, no. 10 (2014): 3310-3323.

[51] H. Kuang and J. D. Lin, “GPNMB: Expanding the Code for Liver-Fat Communication,” Nature Metabolism 1, no. 5 (2019): 507-508.

[52] X. M. Gong, Y. F. Li, J. Luo, et al., “GPNMB Secreted From Liver Promotes Lipogenesis in White Adipose Tissue and Aggravates Obesity and Insulin Resistance,” Nature Metabolism 1, no. 5 (2019): 570-583.

[53] P. S. Harris, C. R. Michel, Y. Yun, et al., “Proteomic Analysis of Alcohol-Associated Hepatitis Reveals Glycoprotein NMB (GPNMB) as a Novel Hepatic and Serum Biomarker,” Alcohol 99 (2022): 35-48.

[54] A. Katayama, A. Nakatsuka, J. Eguchi, et al., “Beneficial Impact of GPNMB and Its Significance as a Biomarker in Nonalcoholic Steatohepatitis,” Scientific Reports 5 (2015): 16920.

[55] J. Wang, H. Wang, W. Yang, et al., “GPNMB Regulates the Differentiation and Transformation of Monocyte-Derived Macrophages During MASLD,” International Immunopharmacology 154 (2025): 114554.

[56] X. Yu, M. Li, C. Wang, and X. Guan, “Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): An Attractive Target in Atherosclerosis,” Biochemical and Biophysical Research Communications 732 (2024): 150386.

[57] Z. Su, J. Y. Sun, M. Gao, W. Sun, and X. Kong, “Molecular Mechanisms and Potential Therapeutic Targets in the Pathogenesis of Hypertension in Visceral Adipose Tissue Induced by a High-Fat Diet,” Frontiers in Cardiovascular Medicine 11 (2024): 1380906.

[58] G. Di Liberto, K. Egervari, M. Kreutzfeldt, et al., “Neurodegenerative Phagocytes Mediate Synaptic Stripping in Neuro-HIV,” Brain 145, no. 8 (2022): 2730-2741.

[59] C. Sala Frigerio, L. Wolfs, N. Fattorelli, et al., “The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques,” Cell Reports 27, no. 4 (2019): 1293-1306.e6.

[60] Y. Ma, C. Zhao, J. Feng, et al., “MSC-sEVS Exacerbate Senescence by Transferring Bisecting Glcnacylated GPNMB,” Stem Cell Research & Therapy 16, no. 1 (2025): 23.

[61] J. Hou, K. X. Chen, C. He, et al., “Aged Bone Marrow Macrophages Drive Systemic Aging and Age-Related Dysfunction via Extracellular Vesicle-Mediated Induction of Paracrine Senescence,” Nature Aging 4, no. 11 (2024): 1562-1581.

[62] Y. Cao, X. Du, J. Yu, et al., “Seno-Antigen-Pulsed Dendritic Cell Vaccine Induce Anti-Aging Immunity to Improve Adipose Tissue Senescence and Metabolic Abnormalities,” Biomedicine & Pharmacotherapy 179 (2024): 117433.

[63] Y. Y. Liu, J. Pang, C. Zhang, et al., “Biofluid GPNMB/Osteoactivin as a Potential Biomarker of Ageing: A Cross-Sectional Study,” Heliyon 10, no. 17 (2024): e36574.

[64] V. M. Ripoll, K. M. Irvine, T. Ravasi, M. J. Sweet, and D. A. Hume, “GPNMB is Induced in Macrophages by IFN-γ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses,” Journal of Immunology 178, no. 10 (2007): 6557-6566.

[65] Q. Wang, Y. Kuroda, L. Yang, et al., “GPNMB Extracellular Fragment Protects Melanocytes From Oxidative Stress by Inhibiting AKT Phosphorylation Independent of CDd44,” International Journal of Molecular Sciences 22, no. 19 (2021): 10843.

[66] F. Sasaki, K. Kumagai, H. Uto, et al., “Expression of Glycoprotein Nonmetastatic Melanoma Protein B in Macrophages Infiltrating Injured Mucosa Is Associated With the Severity of Experimental Colitis in Mice,” Molecular Medicine Reports 12, no. 5 (2015): 7503-7511.

[67] F. Szulzewsky, A. Pelz, X. Feng, et al., “Glioma-Associated Microglia/Macrophages Display an Expression Profile Different From M1 and M2 Polarization and Highly Express GPNMB and Spp1,” PLoS One 10, no. 2 (2015): e0116644.

[68] M. L. Neal, A. M. Boyle, K. M. Budge, F. F. Safadi, and J. R. Richardson, “The Glycoprotein GPNMB Attenuates Astrocyte Inflammatory Responses Through the CD44 Receptor,” Journal of Neuroinflammation 15, no. 1 (2018): 73.

[69] L. Ji, H. Y. Hsu, X. Li, et al., “Localized Dielectric Breakdown and Antireflection Coating in Metal-Oxide-Semiconductor Photoelectrodes,” Nature Materials 16, no. 1 (2017): 127-131.

[70] L. H. Rodan, M. Hauptman, A. M. D'Gama, et al., “Novel Founder Intronic Variant in SLC39A14 in Two Families Causing Manganism and Potential Treatment Strategies,” Molecular Genetics and Metabolism 124, no. 2 (2018): 161-167.

[71] H. Zhang, S. Zhang, X. Dang, L. Lin, L. Ren, and R. Song, “GPNMB Plays an Active Role in the M1/M2 Balance,” Tissue and Cell 74 (2022): 101683.

[72] X. Kong and A. H. Sawalha, “Takayasu Arteritis Risk Locus in IL6 Represses the Anti-Inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex,” Annals of the Rheumatic Diseases 78, no. 10 (2019): 1388-1397.

[73] M. Suda, I. Shimizu, G. Katsuumi, et al., “Glycoprotein Nonmetastatic Melanoma Protein B Regulates Lysosomal Integrity and Lifespan of Senescent Cells,” Scientific Reports 12, no. 1 (2022): 6522.

[74] M. Taya and S. R. Hammes, “Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target,” Steroids 133 (2018): 102-107.

[75] J. P. Zhai, Z. H. Liu, H. D. Wang, G. L. Huang, and L. B. Man, “GPNMB Overexpression Is Associated With Extensive Bone Metastasis and Poor Prognosis in Renal Cell Carcinoma,” Oncology Letters 23, no. 1 (2021): 36.

[76] Y. Ma, Y. Liu, and H. Meng, “Prognostic Evaluation of Oral Squamous Cell Carcinoma Based on Pleiotrophin, Urokinase Plasminogen Activator, and Glycoprotein Nonmetastatic Melanoma Protein B Expression,” Medicine 102, no. 45 (2023): e35634.

[77] B. Heinrich and F. J. Cubero, “FTO/m6A/GPNMB Axis: A Novel Promising Target for Hepatocellular Carcinoma (HCC) Treatment?,” Gut 74, no. 1 (2024): 5-6.

[78] M. Tomihari, J. S. Chung, H. Akiyoshi, P. D. Cruz , and K. Ariizumi, “DC-HIL/Glycoprotein NMB Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells,” Cancer Research 70, no. 14 (2010): 5778-5787.

[79] B. Wang, L. Wang, R. Shang, and L. Xie, “MDSC Suppresses T Cell Antitumor Immunity in CAC via GPNMB in a MyD88-Dependent Manner,” Cancer Medicine 13, no. 1 (2023): e6887.

[80] X. X. Wu, Y. X. Zhao, S. L. Xu, et al., “A Comprehensive Evaluation of circ_0065214/miR-188-3p/GPNMB Axis in Breast Cancer,” Cellular Signalling 115 (2024): 111019.

[81] M. Liguori, E. Digifico, A. Vacchini, et al., “The Soluble Glycoprotein NMB (GPNMB) Produced by Macrophages Induces Cancer Stemness and Metastasis via CD44 and Il-33,” Cellular & molecular immunology 18, no. 3 (2021): 711-722.

[82] Breast Cancer Expert Committee of the National Quality Control Center for Cancer; Expert Committee on Cancer Prevention and Treatment of the Health China Research Center; Society of Clinical Research on Oncology Medications of the China Anti-Cancer Association; Society of Onco-Pathology of the China Anti-Cancer Association. “Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition),” Cancer Innovation 4, no. 3 (2025): e70008.

[83] A. A. N. Rose, M. G. Annis, Z. Dong, et al., “ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain With Angiogenic Properties,” PLoS One 5, no. 8 (2010): e12093.

[84] T. Sjöblom, S. Jones, L. D. Wood, et al., “The Consensus Coding Sequences of Human Breast and Colorectal Cancers,” Science 314 (2006): 268-274.

[85] A. A. N. Rose, A. A. Grosset, Z. Dong, et al., “Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer,” Clinical Cancer Research 16, no. 7 (2010): 2147-2156.

[86] Y. S. Lai, R. Wahyuningtyas, S. P. Aui, and K. T. Chang, “Autocrine VEGF Signalling on M2 Macrophages Regulates PD-L1 Expression for Immunomodulation of T Cells,” Journal of Cellular and Molecular Medicine 23 (2019): 1257-1267.

[87] A. Lin, C. Li, Z. Xing, et al., “The LINK-A lncRNA Activates Normoxic HIF1α Signalling in Triple-Negative Breast Cancer,” Nature Cell Biology 18, no. 2 (2016): 213-224.

[88] D. D. Truong, A. Kratz, J. G. Park, et al., “A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay Between Patient-Derived Fibroblasts and Breast Cancer Cells,” Cancer Research 79, no. 12 (2019): 3139-3151.

[89] G. Maric, M. G. Annis, Z. Dong, et al., “GPNMB Cooperates With neuropilin-1 to Promote Mammary Tumor Growth and Engages Integrin α5β1 for Efficient Breast Cancer Metastasis,” Oncogene 34, no. 43 (2015): 5494-5504.

[90] B. Smuczek, E. S. Santos, A. S. Siqueira, J. J. V. Pinheiro, V. M. Freitas, and R. G. Jaeger, “The Laminin-Derived Peptide C16 Regulates GPNMB Expression and Function in Breast Cancer,” Experimental Cell Research 358, no. 2 (2017): 323-334.

[91] B. Tang, M. Vu, T. Booker, et al., “TGF-β Switches From Tumor Suppressor to Prometastatic Factor in a Model of Breast Cancer Progression,” Journal of Clinical Investigation 112, no. 7 (2003): 1116-1124.

[92] Y. Okita, M. Kimura, R. Xie, et al., “The Transcription Factor MAFK Induces EMT and Malignant Progression of Triple-Negative Breast Cancer Cells Through Its Target GPNMB,” Science Signaling 10, no. 474 (2017): eaak9397.

[93] M. A. Elhinnawi, Y. Okita, K. Shigematsu, et al., “GPNMB Is a Novel Binding Partner of FGFR1 That Affects Tumorigenic Potential Through AKT Phosphorylation in TNBC,” Cancer Science 116, no. 2 (2025): 432-443.

[94] F. Yalcin, H. Haneke, I. E. Efe, et al., “Tumor Associated Microglia/Macrophages Utilize GPNMB to Promote Tumor Growth and Alter Immune Cell Infiltration in Glioma,” Acta Neuropathologica Communications 12, no. 1 (2024): 50.

[95] A. Xiong, J. Zhang, Y. Chen, Y. Zhang, and F. Yang, “Integrated Single-Cell Transcriptomic Analyses Reveal That GPNMB-High Macrophages Promote PN-MES Transition and Impede T Cell Activation in GBM,” EBioMedicine 83 (2022): 104239.

[96] M. Selbach, B. Schwanhäusser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky, “Widespread Changes in Protein Synthesis Induced by microRNAs,” Nature 455, no. 7209 (2008): 58-63.

[97] G. Bao, N. Wang, R. Li, G. Xu, P. Liu, and B. He, “MiR-508-5p Inhibits the Progression of Glioma by Targeting Glycoprotein Non-Metastatic Melanoma B,” Neurochemical Research 41, no. 7 (2016): 1684-1690.

[98] M. Tomihari, S. H. Hwang, J. S. Chung, P. D. Cruz , and K. Ariizumi, “GPNMB Is a Melanosome-Associated Glycoprotein That Contributes to Melanocyte/Keratinocyte Adhesion in a RGD-Dependent Fashion,” Experimental Dermatology 18, no. 7 (2009): 586-595.

[99] R. R. Braeuer, I. R. Watson, C. J. Wu, et al., “Why Is Melanoma so Metastatic?,” Pigment Cell & Melanoma Research 27 (2014): 19e36.

[100] A. Beitner, A. Abu-Abeid, D. Dayan, et al, “Patterns of Expression and Prognostic Implication of Glycoprotein Nonmetastatic Protein B (GPNMB) Expression in Sentinel Lymph Nodes of Melanoma Patients,” Melanoma Research 35, no. 3 (June 2025): 155-161.

[101] J. S. Chung, K. Tamura, P. D. Cruz , and K. Ariizumi, “DC-HIL-Expressing Myelomonocytic Cells Are Critical Promoters of Melanoma Growth,” Journal of Investigative Dermatology 134, no. 11 (2014): 2784-2794.

[102] V. Ramani, T. Teshima, K. Tamura, et al., “Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes From the Pre-Metastatic Niches,” Journal of Investigative Dermatology 138, no. 11 (2018): 2443-2451.

[103] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[104] D. C. Salles, K. Asrani, J. Woo, et al., “GPNMB Expression Identifies TSC1/2/mTOR-Associated and MiT Family Translocation-Driven Renal Neoplasms,” Journal of Pathology 257, no. 2 (2022): 158-171.

[105] O. A. Arosarena, R. A. Dela Cadena, M. F. Denny, et al., “Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas,” Journal of Cellular Physiology 231, no. 8 (2016): 1761-1770.

[106] C. L. Estilo, P. O-charoenrat, S. Talbot, et al., “Oral Tongue Cancer Gene Expression Profiling: Identification of Novel Potential Prognosticators by Oligonucleotide Microarray Analysis,” BMC Cancer 9 (2009): 11.

[107] O. A. Arosarena, E. W. Barr, R. Thorpe, H. Yankey, J. T. Tarr, and F. F. Safadi, “Osteoactivin Regulates Head and Neck Squamous Cell Carcinoma Invasion by Modulating Matrix Metalloproteases,” Journal of Cellular Physiology 233, no. 1 (2018): 409-421.

[108] Y. Kawasaki, H. Suzuki, S. Suzuki, et al., “GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma-Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis,” Pathology and Oncology Research 28 (2022): 1610450.

[109] L. Manevich, Y. Okita, Y. Okano, et al., “Glycoprotein NMB Promotes Tumor Formation and Malignant Progression of Laryngeal Squamous Cell Carcinoma,” Cancer Science 113, no. 9 (2022): 3244-3254.

[110] B. Wang, M. Li, A. Su, et al., “Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients With Esophageal Squamous Cell Carcinoma,” Analytical Cellular Pathology 2022 (2022): 9303081.

[111] Y. Fang, J. Wei, J. Cao, et al., “Protein Expression of ZEB2 in Renal Cell Carcinoma and Its Prognostic Significance in Patient Survival,” PLoS One 8, no. 5 (2013): e62558.

[112] V. Reuter, “The Pathology of Renal Epithelial Neoplasms,” Seminars in Oncology 33, no. 5 (2006): 534-543.

[113] C. Qin, Z. Liu, Y. Yuan, et al., “Glycoprotein Non-Metastatic Melanoma Protein B as a Predictive Prognostic Factor in Clear-Cell Renal Cell Carcinoma Following Radical Nephrectomy,” Molecular Medicine Reports 9, no. 3 (2014): 851-856.

[114] Y. Zhang, C. Qin, X. Zhang, et al., “Knocking Down Glycoprotein Nonmetastatic Melanoma Protein B Suppresses the Proliferation, Migration, and Invasion in Bladder Cancer Cells,” Tumor Biology 39, no. 4 (2017): 1010428317699119.

[115] T. Kimura, Y. Okita, Y. Nagumo, et al., “Glycoprotein Nonmetastatic Melanoma Protein B Impacts the Malignant Potential of Bladder Cancer Cells Through Its Hem-Immunoreceptor Tyrosine-Based Activation Motif,” Pathology International 74, no. 5 (2024): 262-273.

[116] R. Ma, Z. Tang, X. Ye, et al., “Overexpression of GPNMB Predicts an Unfavorable Outcome of Epithelial Ovarian Cancer,” Archives of Gynecology and Obstetrics 297, no. 5 (2018): 1235-1244.

[117] X. Tuo, Y. Zhou, X. Yang, et al., “miR-532-3p Suppresses Proliferation and Invasion of Ovarian Cancer Cells via GPNMB/HIF-1α/HK2 Axis,” Pathology - Research and Practice 237 (2022): 154032.

[118] S. Xu, Y. Fan, D. Li, Y. Liu, and X. Chen, “Glycoprotein Nonmetastatic Melanoma Protein B Accelerates Tumorigenesis of Cervical Cancer In Vitro by Regulating the Wnt/β-Catenin Pathway,” Brazilian Journal of Medical and Biological Research 52, no. 1 (2019): e7567.

[119] K. H. Tsui, Y. L. Chang, T. H. Feng, P. L. Chang, and H. H. Juang, “Glycoprotein Transmembrane NMB: An Androgen-Downregulated Gene Attenuates Cell Invasion and Tumorigenesis in Prostate Carcinoma Cells,” Prostate 72, no. 13 (2012): 1431-1442.

[120] F. Ren, Q. Zhao, B. Liu, et al., “Transcriptome Analysis Reveals GPNMB as a Potential Therapeutic Target for Gastric Cancer,” Journal of Cellular Physiology 235, no. 3 (2020): 2738-2752.

[121] Y. Li, S. Yuan, J. Liu, et al., “CSE1L Silence Inhibits the Growth and Metastasis in Gastric Cancer by Repressing GPNMB via Positively Regulating Transcription Factor MITF,” Journal of Cellular Physiology 235, no. 3 (2020): 2071-2079.

[122] Z. Z. Shi, Y. M. Zhang, L. Shang, et al., “Genomic Profiling of Rectal Adenoma and Carcinoma by Array-Based Comparative Genomic Hybridization,” BMC Medical Genomics 5 (2012): 52.

[123] N. Cortese, R. Carriero, M. Barbagallo, et al., “High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis,” Cancer Immunology Research 11, no. 4 (2023): 405-420.

[124] C. Engblom, C. Pfirschke, and M. J. Pittet, “The Role of Myeloid Cells in Cancer Therapies,” Nature Reviews Cancer 16, no. 7 (2016): 447-462.

[125] E. Peranzoni, J. Lemoine, L. Vimeux, et al., “Macrophages Impede CD8 T Cells From Reaching Tumor Cells and Limit the Efficacy of anti-PD-1 Treatment,” Proceedings of the National Academy of Sciences 115, no. 17 (2018): E4041-E4050.

[126] A. M. Georgoudaki, K. E. Prokopec, V. F. Boura, et al., “Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis,” Cell Reports 15, no. 9 (2016): 2000-2011.

[127] Q. Zhang, Y. He, N. Luo, et al., “Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma,” Cell 179, no. 4 (2019): 829-845.e20.

[128] Y. Sakano, T. Noda, S. Kobayashi, et al., “Tumor Endothelial Cell-Induced CD8+ T-Cell Exhaustion via GPNMB in Hepatocellular Carcinoma,” Cancer Science 113, no. 5 (2022): 1625-1638.

[129] C. Torres, A. Linares, M. J. Alejandre, et al., “The Potential Role of the Glycoprotein Osteoactivin/Glycoprotein Nonmetastatic Melanoma Protein B in Pancreatic Cancer,” Pancreas 44, no. 2 (2015): 302-310.

[130] M. Zamani-Ahmadmahmudi and S. M. Nassiri, “Development of a Reproducible Prognostic Gene Signature to Predict the Clinical Outcome in Patients With Diffuse Large B-Cell Lymphoma,” Scientific Reports 9, no. 1 (2019): 12198.

[131] Z. Wang, X. Ran, S. Qian, et al., “GPNMB Promotes the Progression of Diffuse Large B Cell Lymphoma via YAP1-Mediated Activation of the Wnt/β-Catenin Signaling Pathway,” Archives of Biochemistry and Biophysics 710 (2021): 108998.

[132] Q. Liu, J. Zhang, S. Mao, et al., “GPNMB Expression Associates With Inferior Prognosis in Patients With Small Cell Lung Cancer,” Journal of Cancer 15, no. 10 (2024): 2960-2970.

[133] W. Y. Li, T. T. Zhao, H. M. Xu, et al., “The Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis,” BMC Cancer 19, no. 1 (2019): 145.

[134] L. Li, S. Luo, H. Lin, et al., “Correlation Between EGFR Mutation Status and the Incidence of Brain Metastases in Patients With Non-Small Cell Lung Cancer,” Journal of Thoracic Disease 9, no. 8 (2017): 2510-2520.

[135] M. Tanaka, M. Homme, Y. Yamazaki, R. Shimizu, Y. Takazawa, and T. Nakamura, “Modeling Alveolar Soft Part Sarcoma Unveils Novel Mechanisms of Metastasis,” Cancer Research 77, no. 4 (2017): 897-907.

[136] S. Toda, S. Sato, N. Saito, et al., “TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma,” Cancers 14, no. 3 (2022): 579.

[137] R. Jin, Y. Y. Jin, Y. L. Tang, H. J. Yang, X. Q. Zhou, and Z. Lei, “GPNMB Silencing Suppresses the Proliferation and Metastasis of Osteosarcoma Cells by Blocking the PI3K/Akt/mTOR Signaling Pathway,” Oncology Reports 39, no. 6 (2018): 3034-3040.

[138] E. Gibbons, M. Taya, H. Wu, et al., “Glycoprotein Non-Metastatic Melanoma Protein B Prom Otes Tumor Growth and Is a Biomarker for Lymphangioleiomyomatosis,” Endocrine-Related Cancer 31, no. 6 (2024): e230312.

[139] M. E. Diaz-Ortiz, Y. Seo, M. Posavi, et al., “GPNMB Confers Risk for Parkinson's Disease Through Interaction With Α-Synuclein,” Science 377, no. 6608 (2022): eabk0637.

[140] S. Krasemann, C. Madore, R. Cialic, et al., “The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases,” Immunity 47, no. 3 (2017): 566-581.e9.

[141] P. S. Bandari, J. Qian, G. Yehia, et al., “Hematopoietic Growth Factor Inducible Neurokinin-1 Type: A Transmembrane Protein That Is Similar to Neurokinin 1 Interacts With Substance P,” Regulatory Peptides 111, no. 1-3 (2003): 169-178.

[142] E. Knappe, F. Rudolph, C. Klein, and P. Seibler, “Cytokine Profiling in Human iPSC-Derived Dopaminergic Neuronal and Microglial Cultures,” Cells 12, no. 21 (2023): 2535.

[143] F. Shi, S. Duan, J. Cui, et al., “Induction of Matrix metalloproteinase-3 (MMP-3) Expression in the Microglia by Lipopolysaccharide (LPS) via Upregulation of Glycoprotein Nonmetastatic Melanoma B (GPNMB) Expression,” Journal of Molecular Neuroscience 54, no. 2 (2014): 234-242.

[144] A. Kitani and Y. Matsui, “Alzheimer's Disease Neuroimaging Initiative. Integrative Network Analysis Reveals Novel Moderators of Aβ-Tau Interaction in Alzheimer's Disease,” Alzheimer's Research & Therapy 17, no. 1 (2025): 70.

[145] K. Li, P. Wang, W. Li, et al., “The Association Between Plasma GPNMB and Parkinson's Disease and Multiple System Atrophy,” Parkinsonism & Related Disorders 120 (2024): 106001.

[146] M. Hüttenrauch, I. Ogorek, H. Klafki, et al., “Glycoprotein NMB: A Novel Alzheimer's Disease Associated Marker Expressed in a Subset of Activated Microglia,” Acta Neuropathologica Communications 6, no. 1 (2018): 108.

[147] Z. Zhu, Y. Liu, X. Li, et al., “GPNMB Mitigates Alzheimer's Disease and Enhances Autophagy via Suppressing the mTOR Signal,” Neuroscience Letters 767 (2022): 136300.

[148] Y. Nagahara, M. Shimazawa, K. Ohuchi, et al., “GPNMB Ameliorates Mutant TDP-43-Induced Motor Neuron Cell Death,” Journal of Neuroscience Research 95, no. 8 (2017): 1647-1665.

[149] H. Yang, G. Jin, S. Chen, J. Luo, and W. Xu, “Glycoprotein Non-Metastatic Melanoma B Interacts With Epidermal Growth Factor Receptor to Regulate Neural Stem Cell Survival and Differentiation,” Open Medicine 18, no. 1 (2023): 20230639.

[150] B. Han, M. Y. Bao, Q. Q. Sun, et al., “Nuclear Receptor PPARγ Targets GPNMB to Promote Oligodendrocyte Development and Remyelination,” Brain 148 (2025): awae378.

[151] X. Hou, S. Xiao, X. Xu, M. Qin, X. Cheng, and X. Xu, “Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) Protects Against Neuroinflammation and Neuronal Loss in Pilocarpine-Induced Epilepsy via the Regulation of Microglial Polarization,” Neuroscience 551 (2024): 166-176.

[152] M. Liu, J. Zhu, J. Zheng, et al., “GPNMB and ATP6V1A Interact to Mediate Microglia Phagocytosis of Multiple Types of Pathological Particles,” Cell Reports 44, no. 3 (2025): 115343.

[153] J. Wang, X. Zhang, M. Long, et al., “Macrophage-Derived GPNMB Trapped by Fibrotic Extracellular Matrix Promotes Pulmonary Fibrosis,” Communications Biology 6, no. 1 (2023): 136.

[154] X. Dai, Y. Sun, L. Ma, et al., “A Novel Molecular Mechanism of Vascular Fibrosis in Takayasu Arteritis: Macrophage-Derived GPNMB Promoting Adventitial Fibroblast Extracellular Matrix Production in the Aorta,” Translational Research 255 (2023): 128-139.

[155] M. Cruz Tleugabulova, S. P. Melo, A. Wong, et al., “Induction of a Distinct Macrophage Population and Protection From Lung Injury and Fibrosis by Notch2 Blockade,” Nature Communications 15, no. 1 (2024): 9575.

[156] E. M. King, Y. Zhao, C. M. Moore, et al., “GPNMB and Spp1 Mark a Conserved Macrophage Injury Response Masking Fibrosis-Specific Programming in the Lung,” JCI Insight 9, no. 24 (2024): e182700.

[157] M. Lodge, G. Scheidemantle, V. R. Adams, et al., “Fructose Regulates the Pentose Phosphate Pathway and Induces an Inflammatory and Resolution Phenotype in Kupffer Cells,” Scientific Reports 14, no. 1 (2024): 4020.

[158] J. Beliën, S. Swinnen, R. D'hondt, et al., “CHIT1 at Diagnosis Predicts Faster Disability Progression and Reflects Early Microglial Activation in Multiple Sclerosis,” Nature Communications 15, no. 1 (2024): 5013.

[159] P. S. Tsou and A. H. Sawalha, “Glycoprotein Nonmetastatic Melanoma Protein B: A Key Mediator and an Emerging Therapeutic Target in Autoimmune Diseases,” FASEB Journal 34, no. 7 (2020): 8810-8823.

[160] Q. Li, A. J. Smith, T. W. Schacker, et al., “Microarray Analysis of Lymphatic Tissue Reveals Stage-Specific, Gene Expression Signatures in HIV-1 Infection,” Journal of Immunology 183, no. 3 (2009): 1975-1982.

[161] A. F. F. Belone, P. S. Rosa, A. P. F. Trombone, et al., “Genome-Wide Screening of mRNA Expression in Leprosy Patients,” Frontiers in Genetics 6 (2015): 334.

[162] M. K. Shin, S. W. Shin, M. Jung, H. Park, H. E. Park, and H. S. Yoo, “Host Gene Expression for Mycobacterium Avium Subsp. Paratuberculosis Infection in Human THP-1 Macrophages,” Pathogens and Disease 73, no. 5 (2015): ftv031.

[163] T. Qin, X. Xi, and Z. Wu, “Downregulation of Glycoprotein Non-Metastatic Melanoma Protein B Prevents High Glucose-Induced Angiogenesis in Diabetic Retinopathy,” Molecular and Cellular Biochemistry 478, no. 4 (2023): 697-706.

[164] D. Huo, Y. Y. Liu, C. Zhang, et al., “Serum Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) Level as a Potential Biomarker for Diabetes Mellitus-Related Cataract: A Cross-Sectional Study,” Frontiers in Endocrinology 14 (2023): 1110337.

[165] Z. Fu, S. Li, S. Han, C. Shi, and Y. Zhang, “Antibody Drug Conjugate: The ‘Biological Missile’ for Targeted Cancer Therapy,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 93.

[166] D. A. Yardley, R. Weaver, M. E. Melisko, et al., “EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer,” Journal of Clinical Oncology 33, no. 14 (2015): 1609-1619.

[167] X. Qian, E. Mills, M. Torgov, W. J. LaRochelle, and M. Jeffers, “Pharmacologically Enhanced Expression of GPNMB Increases the Sensitivity of Melanoma Cells to the CR011-vcMMAE Antibody-Drug Conjugate,” Molecular Oncology 2, no. 1 (2008): 81-93.

[168] M. Biondini, A. Kiepas, L. El-Houjeiri, et al., “HSP90 Inhibitors Induce GPNMB Cell-Surface Expression by Modulating Lysosomal Positioning and Sensitize Breast Cancer Cells to Glembatumumab Vedotin,” Oncogene 41, no. 12 (2022): 1701-1717.

[169] L. T. Vahdat, P. Schmid, A. Forero-Torres, et al., “Glembatumumab Vedotin for Patients With Metastatic, GPNMB Overexpressing, Triple-Negative Breast Cancer (‘Metric’): A Randomized Multicenter Study,” NPJ Breast Cancer 7, no. 1 (2021): 57.

[170] V. K. Venishetty, W. J. Geldenhuys, T. B. Terell-Hall, et al., “Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer,” Current Cancer Drug Targets 17, no. 5 (2017): 479-485.

[171] R. L. Wallings, D. A. Gillett, H. A. Staley, et al., “Aso-Mediated Knock-Down of GPNMB in Mutant-GRN and in GRN-Deficient Peripheral Myeloid Cells Disrupts Lysosomal Function and Immune Responses,” Molecular Neurodegeneration 20, no. 1 (2025): 41.

[172] P. A. Ott, A. C. Pavlick, D. B. Johnson, et al., “A Phase 2 Study of Glembatumumab Vedotin, an Antibody-Drug Conjugate Targeting Glycoprotein NMB, in Patients With Advanced Melanoma,” Cancer 125, no. 7 (2019): 1113-1123.

[173] M. Roth, D. M. Barris, S. Piperdi, et al., “Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma,” Pediatric Blood & Cancer 63, no. 1 (2016): 32-38.

[174] B. Li, A. P. Castano, T. E. Hudson, et al., “The Melanoma-Associated Transmembrane Glycoprotein GPNMB Controls Trafficking of Cellular Debris for Degradation and Is Essential for Tissue Repair,” FASEB Journal 24, no. 12 (2010): 4767-4781.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).